Lead Program

SPV Therapeutics’ CDK4/6/9 program represents a next-generation approach to cyclin-dependent kinase inhibition designed to address the biological limitations of first-generation CDK4/6 therapies. While selective CDK4/6 inhibitors have demonstrated clinical benefit, their durability is frequently constrained by adaptive resistance mechanisms involving cell-cycle bypass and transcriptional rewiring.

The program integrates balanced inhibition of CDK4, CDK6, and CDK9 to simultaneously regulate G1 cell-cycle progression and transcriptional programs that sustain tumor survival. This multi-node strategy is intended to address resistance pathways that emerge when cell-cycle control alone is insufficient.

Built on enantiopure, precision small-molecule design, the CDK4/6/9 program is orally bioavailable, development-ready, and supported by an established, scalable synthetic process. The program architecture includes backup and follow-on molecules to support continuity and risk mitigation, along with exploration of emerging modalities such as PROTAC-based approaches derived from the same platform.

Preclinical studies indicate activity in both RB-positive and RB-negative cancer models, including aggressive subtypes such as triple-negative breast cancer (TNBC), where first-generation CDK4/6 inhibitors have shown limited activity. Together, these features position the CDK4/6/9 program as a differentiated, next-generation platform designed to deliver more durable cancer control.

SPV’s programs are designed to modulate core cell-cycle and transcriptional drivers by targeting the CDK4/6/9 pathway in a balanced manner. This strategy seeks to address convergent biological dependencies observed across malignancies characterized by RB pathway dysfunction and TP53 mutation—molecular features collectively present in approximately 50% of human cancers.

Rather than restricting development to the tissue of origin, SPV prioritizes shared proliferative and transcriptional vulnerabilities that contribute to tumor progression and therapeutic resistance.

Reinforcing Checkpoint Control — Constraining Transcriptional Escape

CDK4/6 inhibition reinforces G1 checkpoint regulation.
CDK9 modulation targets transcriptional programs that support survival signaling and adaptive resistance.

By integrating these complementary nodes, SPV’s balanced CDK4/6/9 approach is designed to address both proliferative drive and transcriptional dependency—mechanisms frequently implicated in RB-independence and TP53-mutant tumor biology.

Biology-Defined Exploration

Preclinical evaluations demonstrate activity in RB-independent and TP53-mutant models, supporting continued investigation of a biology-driven, tumor-agnostic development pathway in treatment-refractory cancers.

Tumor settings in which these molecular contexts are prominent include:

• Triple-negative breast cancer (TNBC)
• Small cell lung cancer (SCLC)
• High-grade serous ovarian cancer (HGSOC)
• Additional genomically unstable solid tumors

Programs are investigational and have not received regulatory approval. Statements regarding potential applications are forward-looking and subject to scientific, clinical, and regulatory risks and uncertainties.